Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.